Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

1,973

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

1,973 results for “T cell receptor”

Learn how ShareScore rates datasets ↗
geo24/100

CAR NK cell production from human cord blood cells is enhanced by stimulation of the IL15 receptor on NK progenitor cells

GEO Series GSE295031. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenDec 2025View details →
dryad24/100

Data from: High-throughput sequencing of the T-cell receptor beta chain gene distinguishes two subgroups of cutaneous T-cell lymphoma

[No abstract entered]

opencc-zeroDec 2017View details →
zenodo24/100

Origin and evolutionary malleability of T cell receptor α diversity (zipped files for GitHub code)

<p>Lymphocytes of vertebrate adaptive immune systems acquired the capability to</p> <p>assemble, from split genes in the germline, billions of functional antigen receptors.</p> <p>These receptors show specificity; unlike the broadly tuned receptors of the innate</p> <p>system, antibodies (Ig) expressed by B lymphocytes, for instance, can faithfully</p> <p>distinguish between the two enantiomers of organic acids4 whereas T cell receptors</p> <p>(TCRs) reliably recognize single amino acid replacements in their peptide antigens5.</p> <p>In developing lymphocytes, antigen receptor genes (AgRs) are assembled from a</p> <p>comparatively small set of germline-encoded genetic elements in a process referred</p> <p>to as V(D)J recombination6,7. Potential self-reactivity of some AgRs arising from the</p> <p>quasi-random somatic diversification is suppressed by several robust control</p> <p>mechanisms. For decades, scientists have puzzled over the evolutionary origin of</p> <p>somatically diversifying antigen receptors. It has remained unclear how, at the</p> <p>inception of this mechanism, immunologically beneficial expanded receptor diversity</p> <p>was traded against the emerging risk of destructive self-recognition. Here, we explore</p> <p>the hypothesis that sequence microhomologies marking the ends of recombining</p> <p>elements are the crucial targets of selection determining the outcome of nonhomologous</p> <p>end joining-based repair of DNA double-strand breaks generated during</p> <p>RAG-mediated recombination in early vertebrates. We find that, across the main clades</p> <p>of jawed vertebrates, TCR &alpha; repertoire diversity is best explained by species-specific</p> <p>extents of such sequence microhomologies. Thus, selection of germline sequence</p> <p>composition of rearranging elements emerges as a major factor determining the</p> <p>degree of diversity of somatically generated AgRs.</p>

opencc-by-4.0Jul 2023View details →
ClinicalTrials.gov24/100

Expression of the Inhibitory Receptors on Lymphocytes T Cells After Lung Cancer Surgery.

ClinicalTrials.gov study NCT03549546. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov24/100

Study of CXCR5 Modified EGFE Chimeric Antigen Receptor Autologous T Cells in EGFR- Positive Patients With Advanced Non-small Cell Lung Cancer

ClinicalTrials.gov study NCT04153799. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov24/100

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma

ClinicalTrials.gov study NCT04205838. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov24/100

Treatment of CD19 Chimeric Antigen Receptor T Cells for Pediatric Patients With CD19-positive B-cell Acute Lymphoblastic Leukemia Who Are Indicated for Hematopoietic Stem Cell Transplantation

ClinicalTrials.gov study NCT06247501. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov24/100

Chimeric Antigen Receptor T Cells Targeting Glypican-3

ClinicalTrials.gov study NCT03884751. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov24/100

The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies

ClinicalTrials.gov study NCT04184414. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov24/100

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

ClinicalTrials.gov study NCT06253520. IPD Sharing: YES. Countries: 1. Publications: 0.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov24/100

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Pros

ClinicalTrials.gov study NCT06094842. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov24/100

A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies

ClinicalTrials.gov study NCT07135466. IPD Sharing: YES. Countries: 1. Publications: 0.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov24/100

Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer

ClinicalTrials.gov study NCT03727724. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov24/100

3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA

ClinicalTrials.gov study NCT02439788. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov24/100

Natural Killer Cells Functions, Tumoral Escape to Immune System and Regulation of Natural Cytotoxixity Receptors in Haematological Malignancies

ClinicalTrials.gov study NCT01915992. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov24/100

Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma

ClinicalTrials.gov study NCT05577000. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov24/100

A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

ClinicalTrials.gov study NCT01887886. IPD Sharing: Not stated. Countries: 8. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov24/100

Program Cell Death Receptor 1 in Mycobacterium Avium Complex Lung Disease

ClinicalTrials.gov study NCT02779049. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov24/100

Anti-Angiotensin-Receptor 1 (ATR1)-, Anti-Endothelin-Receptor A (ETRA)-Antibodies and T Cells in Cardiomyopathy

ClinicalTrials.gov study NCT02319590. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov24/100

Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.

ClinicalTrials.gov study NCT06071624. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record